Try GOLD - Free
AIOCD asks traders to strictly comply with ban on 35 FDCs
Chronicle Pharmabiz
|December 11, 2025
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
Issued under the directive of AIOCD president J S Shinde and general secretary Rajiv Singhal, the circular, dated November 19, 2025 moves to protect the retail trade sector from impending regulatory action. The move follows reports that state-level FDA authorities have already begun insisting that member chemists immediately cease the sale and purchase of these concerned FDC formulations.
The primary impetus for this aggressive internal advisory is the CDSCO circular of April 11 this year, which confirmed the ban. The Central Drugs Standard Control Organization found that these FDCs were licensed for manufacture, sale, and distribution without the mandatory prior evaluation of safety and efficacy as required under the NDCT Rules 2019.
The regulatory body warned that the unapproved nature of these combinations compromise patient safety, potentially leading to adverse drug reactions and serious health hazards, necessitating their market removal.
The AIOCD has clearly outlined the points that are advised to the state and UT branches to ensure a uniform, compliant, and protected trade environment. State and UT bodies are specifically instructed to immediately circulate the full list of banned FDCs to all local stockists and retail chemists. The national body further instructs the state branches to insist all member chemists stop the sale and purchase of these products with immediate effect.
This story is from the December 11, 2025 edition of Chronicle Pharmabiz.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Chronicle Pharmabiz
Chronicle Pharmabiz
Devices sector raises concern over notification proposing fee for tests
THE medical devices industry has raised concern over the Department of Health and Family Welfares' draft notification introducing fee for test or evaluation of medical devices and mandating inclusion of licence number of sub contractor on the product labels. The Department published the draft notification on April 10, proposing various amendments to the Medical Devices Rules (MDR), 2017 including introduction of fee for test or evaluation of 11 types of tests or evaluation.
2 mins
April 30, 2026
Chronicle Pharmabiz
Panel asks DoP to take efforts to decrease imported content in medical devices
OBSERVING that a majority of the medical devices market is addressed by imports, the Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceuticals (DOP) to take measures including promotion of stronger collaboration among the industry, academic institutions and research organisations to accelerate indigenous development of advanced medical devices.
1 mins
April 30, 2026
Chronicle Pharmabiz
AI in endoscopy will improve detecting early-stage cancer markers
INDIA has been moving steadily towards better cancer care. However, many cancers in India are still detected late, especially those in the digestive system.
2 mins
April 30, 2026
Chronicle Pharmabiz
Telangana appoints DG of DCA as compounding authority
IN a significant move to streamline regulatory compliance under the newly enacted Jan Vishwas provisions, the Government of Telangana has officially designated the Director General (DG) of the state’s Drugs Control Administration (DCA), Shahnawas Quasim, as the 'Compounding Authority'.
2 mins
April 30, 2026
Chronicle Pharmabiz
AIOCD seeks PM's intervention against e-pharmacies
THE All India Organisation of Chemists & Druggists (AIOCD), representing over 12.40 lakh pharmacists and distributors, has formally petitioned Prime Minister Narendra Modi to intervene against the unregulated growth of e-pharmacies and predatory pricing by large corporate entities.
1 mins
April 30, 2026
Chronicle Pharmabiz
Shed The Cavalier Attitude
A Parliamentary Panel has recently asked the Department of Pharmaceuticals (DoP) to take corrective steps to remove any administrative and procedural delays related to the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.
2 mins
April 30, 2026
Chronicle Pharmabiz
DCOIWA slams new DCGI recruitment rules, cites dilution of tech standards
THE Drugs Control Officers (I) Welfare Association (DCOIWA), the national body of drug regulatory officers in the country, has criticised the Union Heath Ministry's newly notified recruitment rules for the post of DCGI, labelling them as a serious policy lapse.
1 mins
April 30, 2026
Chronicle Pharmabiz
Experts highlight the need for data exclusivity to protect MSMES
EXPERTS have highlighted the need for clinical data exclusivity in order to protect MSME drug innovators in India.
2 mins
April 30, 2026
Chronicle Pharmabiz
Mid-sized hospitals in Tier-2 cities stranded in a financial vacuum: Expert
MID-sized hospitals in Tier-2 cities are currently trapped in a financial vacuum. This is because funding usually arrives either too early as venture capital or too late as a financial buyout, said Rakshith Rangarajan, equity fund manager, Inviga Investment Advisors.
2 mins
April 30, 2026
Chronicle Pharmabiz
Indian healthcare sector faces escalating cyber risks
INDIAN healthcare sector is confronting a surge in cyber threats as increasingly complex hospital IT ecosystems create multiple vulnerabilities for potential breaches.
2 mins
April 30, 2026
Listen
Translate
Change font size
